Xtl Biopharmaceuticals (XTLB) EBT Margin (2011 - 2024)

Xtl Biopharmaceuticals (XTLB) posted quarterly EBT Margin of 155.02% for Q4 2024, up 55.02% on a QoQ basis from 100.0% in Q3 2018.

Xtl Biopharmaceuticals (XTLB) EBT Margin (2011 - 2024) Analysis & Trends

Xtl Biopharmaceuticals (XTLB) has reported EBT Margin for 7 consecutive years, with 155.02% the latest figure, recorded in Q4 2024.

Quarterly EBT Margin changed N/A year-over-year to 155.02% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 20.11% (changed N/A YoY) and the FY2025 annual result came in at 138.25%, up 3892.0% from the prior year.
EBT Margin climbed to 155.02% in Q4 2024 per XTLB's latest filing, from 100.0% in the prior quarter.
Over the last five years, EBT Margin for XTLB reached as high as 155.02% in Q4 2024 and fell as low as 155.02% in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn	17.13%
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn	41.95%
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn	23.05%
7	Belite Bio	62.72 Bn	62.72 Bn	-	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn	34.77%
9	Revolution Medicines	37.35 Bn	37.35 Bn	-	-
10	Xtl Biopharmaceuticals	2.58 Bn	2.58 Bn	-	-

Download Data